Aurobindo Pharma is currently trading at Rs. 728.80, up by 3.65 points or 0.50% from its previous closing of Rs. 725.15 on the BSE.
The scrip opened at Rs. 734.60 and has touched a high and low of Rs. 735.30 and Rs. 725.10 respectively. So far 49767 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1063.75 on 11-May-2021 and a 52 week low of Rs. 620.55 on 22-Nov-2021.
Last one week high and low of the scrip stood at Rs. 732.30 and Rs. 690.00 respectively. The current market cap of the company is Rs. 42852.62 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 37.23% and 10.93% respectively.
Aurobindo Pharma has received the Drugs Controller General of India’s (DCGI’s) permission to manufacture and distribute its in-licensed generic version of MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback’s Molnupiravir, to be marketed as Molnaflu. Earlier this year, Aurobindo had signed a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore (MSD), a subsidiary of Merck & Co. (US) to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMIC), including India.
Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for the treatment of mild-to-moderate COVID -19 in adults. It has also been recently approved by the U.S. Food and Drug Administration (USFDA) and under Emergency Use Authorisation (EUA).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.